SynBiotic SE (SBX) - Total Liabilities
Based on the latest financial reports, SynBiotic SE (SBX) has total liabilities worth €17.83 Million EUR (≈ $20.85 Million USD) as of December 2022. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SynBiotic SE (SBX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
SynBiotic SE - Total Liabilities Trend (2019–2024)
This chart illustrates how SynBiotic SE's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SBX asset base.
SynBiotic SE Competitors by Total Liabilities
The table below lists competitors of SynBiotic SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
XIAO-I Corporation American Depositary Shares
NASDAQ:AIXI
|
USA | $119.18 Million |
|
Indo Oil Perkasa PT
JK:OILS
|
Indonesia | Rp205.89 Billion |
|
Costain Group PLC
LSE:COST
|
UK | GBX325.40 Million |
|
Beneficient Class A Common Stock
NASDAQ:BENF
|
USA | $337.53 Million |
|
A.G.Barr PLC
LSE:BAG
|
UK | GBX168.60 Million |
|
Conduit Holdings Ltd
LSE:CRE
|
UK | GBX1.36 Billion |
|
Fiberweb (India) Limited
NSE:FIBERWEB
|
India | Rs166.67 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down SynBiotic SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SBX equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SynBiotic SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SynBiotic SE (2019–2024)
The table below shows the annual total liabilities of SynBiotic SE from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €24.70 Million ≈ $28.88 Million |
+26.09% |
| 2023-12-31 | €19.59 Million ≈ $22.90 Million |
+9.85% |
| 2022-12-31 | €17.83 Million ≈ $20.85 Million |
-25.45% |
| 2021-12-31 | €23.92 Million ≈ $27.97 Million |
+151.01% |
| 2020-12-31 | €9.53 Million ≈ $11.14 Million |
+381114.48% |
| 2019-12-31 | €2.50K ≈ $2.92K |
-- |
About SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. T… Read more